Gujarat Themis Biosyn cash flow

Latest FY26
Cash from operations
₹48.8cr−46.4% on FY25
Capital spending
₹173cr+48.5% on FY25
Free cash flow
−₹124cr−₹25.1 cr in FY25
Cash from financing
₹115cr+341.8% on FY25
₹ crore except per share
Tap a line for its trendLast 12Mto Jun 2026FY26Mar 2026FY25Mar 2025
Adjustments to reconcile profit — non-cash items
—12.95.7
—2.90.4
—0.0−0.7
—0.0−0.2
—−0.2−0.1
—−0.10.0
Changes in working capital
—−10.4−1.7
—−29.7−4.2
—1.40.0
—−4.050.8
—0.0−14.2
—−2.10.8
—22.20.0
—0.04.8
—2.50.0
—1.71.1
—0.0−0.5
—0.50.0
—0.00.1
Cash from operating activities
65.162.165.5
—−2.342.0
—59.8108
—−0.40.0
—10.616.5
—48.891.0
Cash from investing activities
—173116
—−0.0−0.0
—0.34.3
—−172−112
Cash from financing activities
—13029.9
—1.31.6
—6.40.4
—7.31.8
—11526.0
—−8.65.2
—−8.65.2
Reference items
82.475.568.8
47.4%45.6%45.7%
−124−124−25.1
—−0.2—
−₹11.36−₹11.36−₹2.31
—1.04×1.87×
—10.616.5
—6.40.4
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

GUJTHEM₹355.55

Gujarat Themis Biosyn Limited

· Pharma & Health
₹ CrorePeersRPGLIFEGUFICBIOORCHPHARMAUNICHEMLABFDCIOLCPMOREPENLABINNOVACAPMcap ₹3,874 Cr
View
In ₹ Crore except Per Share
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation5.712.9—
+ Finance Costs0.42.9—
+ Interest Income-0.70.0—
+ Fair Value (Gains) / Losses-0.20.0—
+ Unrealised FX (Gain) / Loss-0.1-0.2—
+ Other Non-cash Items0.0-0.1—
Changes in Working Capital
+ Inventories-1.7-10.4—
+ Trade Receivables — Current-4.2-29.7—
+ Other Financial Assets — Current0.01.4—
+ Other Financial Assets — Non-current50.8-4.0—
+ Other Non-current Assets-14.20.0—
+ Other Bank Balances0.8-2.1—
+ Trade Payables — Current0.022.2—
+ Trade Payables — Non-current4.80.0—
+ Other Financial Liabilities — Current0.02.5—
+ Other Financial Liabilities — Non-current1.11.7—
+ Other Current Liabilities-0.50.0—
+ Provisions — Current0.00.5—
+ Provisions — Non-current0.10.0—
Cash from Operating Activities
Profit Before Tax (per I/S)65.562.165.1
+ Total Adjustments (incl. Working Capital)42.0-2.3—
Cash from Operations (pre-tax)107.559.8—
+ Interest Received — Operating0.0-0.4—
+ Income Taxes Paid16.510.6—
Cash from Operating Activities91.048.8—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)116.2172.5—
+ Loans & Advances Repaid-0.0-0.0—
+ Interest Received — Investing4.30.3—
Cash from Investing Activities-111.8-172.3—
Cash from Financing Activities
+ Proceeds from Borrowings29.9130.0—
+ Payment of Lease Liabilities1.61.3—
+ Interest Paid0.46.4—
+ Dividends Paid1.87.3—
Cash from Financing Activities26.0114.9—
Net Changes in Cash (pre-FX)5.2-8.6—
Net Changes in Cash5.2-8.6—
Reference Items
EBITDA68.875.582.4
EBITDA Margin %45.6545.5547.43
Free Cash Flow (CFO − Capex)-25.1-123.8-123.8
Free Cash Flow to Equity—-0.2—
Free Cash Flow per Basic Share-2.31-11.36-11.36
Cash Flow to Net Income1.871.04—
Cash Paid for Taxes16.510.6—
Cash Paid for Interest0.46.4—
As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.